Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EBITDA (2016 - 2025)

Historic EBITDA for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $75.5 million.

  • Ironwood Pharmaceuticals' EBITDA rose 19444.53% to $75.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.2 million, marking a year-over-year increase of 2415.39%. This contributed to the annual value of $93.1 million for FY2024, which is 10984.99% up from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' EBITDA is $75.5 million, which was up 19444.53% from $45.3 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' EBITDA registered a high of $391.3 million during Q2 2021, and its lowest value of -$1.1 billion during Q2 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' median EBITDA value was $39.9 million (recorded in 2021), while the average stood at -$4.1 million.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' EBITDA surged by 145254.32% in 2021 and then plummeted by 303818.23% in 2023.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' EBITDA stood at $41.4 million in 2021, then grew by 18.11% to $48.9 million in 2022, then fell by 23.08% to $37.6 million in 2023, then decreased by 16.22% to $31.5 million in 2024, then surged by 139.7% to $75.5 million in 2025.
  • Its EBITDA was $75.5 million in Q3 2025, compared to $45.3 million in Q2 2025 and -$29.1 million in Q1 2025.